TLX-300

N/A

Report date: 2025/09/19 16:47:31

Base Information

Drug NameTLX-300
Drug Alias Name89Zr-olaratumab (Telix Pharmaceuticals)Radiolabelled Olaratumab (Telix Pharmaceuticals)Radionuclide olaratumab conjugat (Telix Pharmaceuticals)TLX300TLX-300 +[6] 
ClassificationRadiation-emitting products > Radioactive diagnostic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4] 
Mechanisms of ActionPlatelet-derived growth factor receptor alpha inhibitorsPositron-emission tomography enhancersRadionuclide imaging enhancers
TargetsPlatelet-derived growth factor receptor alpha
Therapy Area/IndicationsSoft Tissue NeoplasmsSarcomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesTelix Pharmaceuticals (Innovations) Pty LtdTelix Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsSoft Tissue NeoplasmsSarcoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A